Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852587 · ClinicalTrials.gov registry record · Phase 1
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Not yet
- Registry status
- Phase 1
- Development phase
- 99
- Enrollment target
NCT05852587 is a Phase 1 study that has not yet begun recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 99 participants.
The verdict
NCT05852587, a Phase 1 study, has not yet begun recruiting, sponsored by Brigham and Women's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 99 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients. A total of 99 patients who meet eligibility criteria will be randomized 1:1:1 to one of two xylitol doses or placebo arm. All arms will receive an identical capsule dosing for four weeks. Microbiome assessment and C. difficile testing will be performed at baseline, week 4, 8, 26, and 52.
Interventions
- DRUG Placebo
- DRUG Xylitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2033-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05852587
The ClinicalTrials.gov registry entry for NCT05852587 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05852587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05852587 about?
NCT05852587 is a clinical study titled "Xylitol Use for Decolonization of C. Difficile in Patients With IBD". This is a randomized, placebo-controlled, dose-ranging study to assess the safety and efficacy of xylitol as an oral therapeutic for decolonization of C. difficile in IBD patients. A total of 99 patients who meet eligibility criteria will be randomized 1:1:1 to one of two xylitol doses or placebo ar...
What is the current status of trial NCT05852587?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2026-08-01. Estimated completion is 2033-01-01.
What interventions are being tested in trial NCT05852587?
The interventions under investigation include: Placebo (DRUG), Xylitol (DRUG).
Who is sponsoring clinical trial NCT05852587?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.